One thing you own but can’t rent is your health. During a recent trip to the Netherlands, I enjoyed the opportunity to engage in some very thought-provoking dialogue at the AESGP pan-European self-care medicines conference about ways that patients can be better owners of their health in Europe and around the world.
An idea that stood out involves the role of diagnostic testing in self-care, known as over-the-counter medicine in some parts of the world. It’s an area of growing interest for me because patients can become more aware of their conditions and react accordingly. Common over-the-counter diagnostics include glucose monitors or pregnancy tests – both help patients to determine whether additional medical care is required or if the issue can be treated at home. Read more.
Helping patients is at the heart of everything we do at Mylan. That’s why I’m thrilled about today’s FDA approval of Mylan’s Fulphila™, the first FDA approved biosimilar to the biologic Neulasta® (pegfilgrastim). The news represents a big win in Mylan’s efforts to expand treatment options for cancer patients.
Biologic medicines have become the standard of care for cancer and other diseases, but they are costly and complex to make. Mylan’s strong scientific expertise and ability to innovate positions us to bring versions of these medicines, called biosimilars, to patients. By doing so, we hope to create competition, increase affordability and get patients the medicines they need.
Mylan is already one of the largest suppliers of cancer medicines in the U.S., and both biosimilars we’ve had approved here are oncology medicines. But we’re not stopping there. We have more than 400 oncology products in our pipeline and look forward to continuing to meet the needs of cancer patients at every stage of their journey.
Thanks to our partner, Biocon, and the countless Mylan employees who worked hard to make today’s important milestone a reality. Together, we are truly making a difference for patients.
Every day, I consider myself extremely fortunate to wake up knowing that, regardless of what challenges the day may hold, I work for a company that, at its core, is committed to delivering better health for a better world.
I also consider daily the various interests of our company’s many stakeholders and the responsibility we have to serve them, while also upholding our fundamental mission. For nearly 60 years, we’ve fought to expand access to high quality medicine for patients around the world. We continue to do so, thanks to our workforce of approximately 35,000 people who consistently and passionately drive our progress. We also appreciate and value the opportunity to collaborate with customers and partners to meet our goals. At the same time, we’re focused on delivering consistent and reliable results for shareholders. It’s a balance we call “doing good” and “doing well,” meaning that our mission drives our long-term business model and sustainability and vice versa.
Mylan’s recently released 2017 Better Health for a Better World Progress Report on Global Social Responsibility is one way we continue to tell our story of impact – and I couldn’t be prouder to share it with you. View the report here.
Yesterday Mylan hosted an Investor Day in New York. I was energized to share our story with analysts and shareholders, including a view of our differentiated business model in which doing good drives a continued ability to do well. For nearly 60 years, Mylan’s core purpose has been to provide access to high quality medicine. Over the decades, as we’ve expanded these efforts, the company has had to achieve tremendous diversification across its commercial, operational and scientific platforms. With this expanded access and greater diversification, the durability and resilience of our business has grown, which in turn allows us to reinvest in our core purpose. It’s an engine that signifies Mylan is #BuiltToLast and that the best is yet to come! Please check out my interview with Andy Serwer at YahooFinance!
March 29, 2018
An HIV Success Story
Mylan continues to fight for access to high-quality medicine and one of our best success stories is for people living with HIV. While I continue to be an advocate to fix our broken healthcare system and work to find solutions for the patient at the pharmacy counter, I equally want to call attention to what is working. Read more.
March 8, 2018
From the Family Room to the Board Room
I can't help but wonder what the world might look like today if all – not just half – of the world’s great minds over the centuries had been recognized and their full potential tapped. I think about illnesses that might now be distant memories, injustices that could have been avoided and great works of art that may have changed the world for the better. For all these reasons and more, I regard this year’s International Women’s Day’s theme, #PressforProgress, as a poignant reminder of the work still ahead of us to achieve gender equality. Read more.
March 2, 2018
Mylan Is That Company!
I recognize that a recurring theme across the U.S. healthcare sector right now is the ongoing challenges that many companies are facing.
Those challenges are causing many to wonder what the future holds for our industry. Read more.
February 21, 2018
I’m passionate about Mylan’s work to fight HIV/AIDS. More than 40% of people being treated around the world depend on a Mylan product.
This week, our work to continue to set new standards for affordable access for patients in countries hardest hit by HIV/AIDS took another step forward. The U.S. Food and Drug Administration announced the tentative approval under the U.S. President's Emergency Plan for AIDS Relief of our Dolutegravir, Emtricitabine and Tenofovir Alafenamide Tablets.
The product will be immediately available in developing countries as a first-line regimen for people being treated for the disease. The tablet will be the smallest sized single-tablet regimen available for patients in the developing world. And by offering 90-day and 30-day packages, we hope patients can make fewer trips to clinics to get refills.
Our commitment to continue to innovate and expand access has never been stronger. The world needs more cost competitive and clinically effective products like this one, which is why Mylan is proud to work with partners to make it available and help reach the more than 15 million people living with HIV worldwide who still need access to treatment. You can read our press release here.
January 31, 2018
Disrupting the U.S. Healthcare System
I continue to be a strong proponent for disrupting and reimagining the U.S. healthcare system, and I believe employers will play a crucial role. In this recent media interview, I share some of my ideas.
January 23, 2018
Experiencing Davos for the First Time
Anticipation, expectation and excitement all ran high as I began my journey through Davos today to participate in the World Economic Forum. I am humbled by my surroundings – both the snow-capped mountains as well as the thousands of people participating in the forum. Read more
January 9, 2018
Great Day at a Great Conference
Excited to be here at J.P. Morgan’s Healthcare Conference. Mylan is off to a great start to 2018, and I look forward to continuing the important discussion about healthcare and challenging the status quo. I started early this morning with a media interview with Fox Business’s Maria Bartiromo. Read more
December 18, 2017
Almost Heaven. West Virginia.
The world is a very big place, but no matter how far away I travel, West Virginia holds a special place in my heart. It’s where I was born and raised, it’s where Mylan was founded nearly 57 years ago and it’s where I began my career with the company. Read more
December 17, 2017
Our Hearts Are Still and Always With Those in Puerto Rico
Happy 30th anniversary, Mylan Puerto Rico!
You are part of Puerto Rico’s proud tradition of pharmaceutical manufacturing, and your quality products help deliver better health in the U.S. and Canada – and as far away as Japan. The extra care and attention required to make the important products you do – for conditions such as cancer, autoimmune disorders and diabetes – calls for an exceptional team. I have no doubt that the many patients who use your products deeply appreciate your commitment to excellence. Read more
December 5, 2017
States Can and Should Disrupt Healthcare
Democratic governors gathered this week in New Orleans, where I was invited to participate in a panel discussion regarding the U.S. healthcare system and its future.
I took the opportunity to share some remarkable statistics about the generic pharmaceuticals industry and Mylan’s role within it. For example, did you know that generics now fill 90% of all prescriptions dispensed in the nation but account for only 27% of drug-spending costs? That means brands fill the remaining 10% of all prescriptions yet make up 73% of drug spending. Read more
December 1, 2017
Mylan’s Commitment to Expand Access to Cancer Treatments Reaches New Milestone
Mylan is celebrating an important victory today on behalf of patients in the U.S. who have HER2-positive breast cancer or metastatic stomach cancer.
The Food and Drug Administration just approved Ogivri™, the first biosimilar in the U.S. to Herceptin® (trastuzumab), a biologic drug that’s part of a new generation of targeted therapies which have radically changed the way cancer is treated. Mylan co-developed Ogivri with Biocon. The approval is significant because of the tremendous value biosimilars offer. Read More
December 1, 2017
World AIDS Day
Today is World AIDS Day, and on this occasion, we mourn the millions of lives lost to the disease already, support and encourage those living with it, and renew our commitment to defeating the virus once and for all. Read More
October 24, 2017
What a Difference a Decade Makes
Ten years ago this month, Mylan completed its acquisition of Merck KGaA’s generics business. Through this watershed event we essentially transformed ourselves overnight into one of the world’s leading specialty and generic pharmaceuticals companies.
Mylan already was an American success story, having helped establish generic drugs by the end of the 20th century as the backbone of the U.S. healthcare system. But the industry was changing. Our customers were consolidating, lower-cost imported drugs were flooding into the country and brand pharma companies had become far more aggressive in their attempts to impede competition. Read More
September 25, 2017
Equality for all
Over the weekend, the film “Battle of the Sexes” premiered – it chronicles the 1973 tennis match between Billie Jean King and Bobby Riggs, which remains the most watched televised sports event of all time. I was fortunate to get a sneak peek of the movie, thanks to an invitation from my friend Billie Jean King, at its Los Angeles premier. The film reminded me of how far we’ve come as a society in terms of how we value the contributions and capabilities of both men and women. It also reminded me of how far we’ve yet to go and that men and women are still fighting globally for equal access to opportunity. Read More
September 5, 2017
Better Health for a Better West Virginia
Last week, I was honored to speak at the West Virginia Chamber’s annual business summit in White Sulphur Springs, W.Va. It’s always great to come home, and I am proud to call West Virginia my home as well as Mylan’s birthplace. As you know, White Sulphur Springs is where Mylan was founded more than 55 years ago by two army buddies who had a vision to provide access to medicine to the good people of rural West Virginia. Today, Mylan is still doing the same thing -- just now on a global scale. Read More
August 25, 2017
Parking lot picnics: a great way to bring people together
Sometimes the simplest ways to build friendships and celebrate community are the best ones. This week, I was honored to join Mylan employees in Pittsburgh for a picnic in our office parking lot. We recognized colleagues who achieved milestone anniversaries in 2017, including our President Rajiv Malik who has played an invaluable leadership role with Mylan for 10 years. Read More
August 7, 2017
Sharing Mylan’s Impact on U.S. Healthcare at the 2017 DGA Policy Conference
I appreciated the opportunity to attend the Democratic Governors Association 2017 Summer Policy Conference in Aspen over the weekend, where I shared Mylan’s great story with governors, their staff and fellow attendees. I emphasized the scale of our impact on U.S. healthcare – over the past decade Mylan has contributed to more than $180 billion in healthcare savings as a leading manufacturer of generic pharmaceuticals. Read More
June 12, 2017
Generics and Biosimilars Drive Access and Savings for the U.S. Healthcare System
The Association for Accessible Medicines today released their 2017 Generic Drug Access & Savings in the U.S. report. I am always keen to read these findings, because it reinforces how Mylan along with our generics industry peers are part of the solution to address the critical economic burden faced by the U.S. healthcare system.
In the last decade, generic drugs have saved the U.S. healthcare system $1.67 trillion, generating $253 billion in savings in 2016 alone. Nearly 3.9 billion of the total 4.4 billion prescriptions dispensed in the U.S. are for generics. That’s equivalent to generics accounting for almost 90% of prescriptions, but only 26% of the cost. Read More
May 30, 2017
Sustaining a Culture that Delivers Better Health for a Better World
I’m truly humbled and honored that tomorrow evening I’ll be receiving Hugh O’Brian Youth’s (HOBY) Albert Schweitzer Leadership Award. HOBY gives this award to individuals who, “through their leadership, have made significant contributions to the education and motivation of youth.”
For those who may not be familiar with HOBY, it was created by actor and humanitarian Hugh O’Brian to help cultivate tomorrow’s leaders by inspiring a global community of youth and volunteers to a life dedicated to leadership, service and innovation. In creating the organization, O’Brian was acting on Dr. Schweitzer’s belief that the most important thing in education is to teach young people to think for themselves – a life lesson that was instilled in me at a very young age. Read More
May 16, 2017
Honoring National Women’s Health Week
Sunday marked the beginning of National Women’s Health Week, an annual observance led by the U.S. Department of Health and Human Services (HHS) Office on Women's Health. HHS’s message of empowering women to make their health a priority is a powerful one, and one that we take seriously at Mylan.
What’s remarkable is that the public dialogue around women’s health has only just begun. We know, unfortunately, that women are at a higher risk of facing a range of potential health concerns. Not only that, but certain diseases also can manifest themselves very differently in men than women. It wasn’t until the past couple of decades that there was an acknowledgement by regulatory bodies, government agencies and the scientific community that women were not adequately enrolled in clinical trials. We are now scratching the surface on how the biological differences between men and women can have a meaningful impact on how diseases affect the two sexes. Read More
February 15, 2017
A New Look for an Industry That's Always Been About Access
I had the pleasure of attending the Generic Pharmaceutical Association’s annual meeting this week. It’s an important meeting for our industry to rally behind and align on how we can continue to play a meaningful role in expanding access to high quality medicines for patients.
Having just finished a one-year term as chair of the association, this year’s event was particularly meaningful as GPhA launched its new brand – the Association for Accessible Medicines -- to better reflect what our industry means to America's healthcare system. Read More